Literature DB >> 25194306

Growth hormone secreting pituitary microadenomas and empty sella - An under-recognized association?

Weiming Liu1, Hui Zhou2, Marian Christoph Neidert3, Christoph Schmid4, René-Ludwig Bernays5, Ming Ni1, Dabiao Zhou1, Wang Jia1, Guijun Jia6.   

Abstract

OBJECTIVE: To describe an association of growth hormone (GH) secreting pituitary microadenomas and empty sella (ES), which has been described in case reports - the underlying mechanisms are unclear.
METHODS: We retrospectively analyzed patients operated for GH-producing pituitary adenomas between February 2004 and February 2009. Magnetic resonance imaging (MRI), computed tomography (CT) imaging, and pituitary function testing were performed. All cases underwent transsphenoidal surgery (TSS). Mean follow up was 38 months (range 12-80 months).
RESULTS: Out of 152 patients with acromegaly due to GH-producing pituitary adenomas (female:male=73:79; age range 17-63 years), 69 patients had microadenomas (45.4%; 38 females, 31 males). We found 14 cases (14/69, 20.3%), all microadenomas, with presurgical evidence of ES - 10 females (71%) and 4 males (29%) (female:male=2.5:1). When compared with 103 patients with GH-negative microadenomas treated in the same time period (ES in 4 of 103; 3.9%), ES was highly significantly associated with GH production by the microadenoma (p=0.001). In acromegalics with empty sella, no cases of ectopic adenoma were found. Postoperatively, GH and IGF-1 levels fell in all patients, and 7 cases had random GH and IGF-1 levels consistent with cure.
CONCLUSION: The combination of GH-producing microadenomas and empty, enlarged sella is not rare. In this setting, preoperative CT scans are very useful and the transsphenoidal approach is efficient and safe. The mechanism underlying the association of GH-producing microadenomas and empty sella remains unclear and requires further studies.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Empty sella; Growth hormone (GH); Microadenomas; Neuroimaging; Transsphenoidal approach

Mesh:

Year:  2014        PMID: 25194306     DOI: 10.1016/j.clineuro.2014.08.012

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  6 in total

1.  Ectopic Pituitary Adenomas Presenting as Sphenoid or Clival Lesions: Case Series and Management Recommendations.

Authors:  Bobby A Tajudeen; Edward C Kuan; Nithin D Adappa; Joseph K Han; Rakesh K Chandra; James N Palmer; David W Kennedy; Marilene B Wang; Jeffrey D Suh
Journal:  J Neurol Surg B Skull Base       Date:  2016-09-09

2.  Clinical characteristics of acromegalic patients with empty sella and their outcomes following transsphenoidal surgery.

Authors:  Yasuo Sasagawa; Yasuhiko Hayashi; Osamu Tachibana; Masahiro Oishi; Issei Fukui; Hideaki Iizuka; Mitsutoshi Nakada
Journal:  Pituitary       Date:  2017-08       Impact factor: 4.107

Review 3.  Developmental and Functional Effects of Steroid Hormones on the Neuroendocrine Axis and Spinal Cord.

Authors:  L Zubeldia-Brenner; C E Roselli; S E Recabarren; M C Gonzalez Deniselle; H E Lara
Journal:  J Neuroendocrinol       Date:  2016-07       Impact factor: 3.627

4.  Primary empty sella associated with pituitary adenoma diagnosed by inferior petrosal sinus blood sampling.

Authors:  Hang Su; Jian Zhou; Yu-Qian Bao; Yi-Fei Mo; Wei-Tian Zhang; Jun-Gong Zhao; Xiao-Jing Ma; Wei-Ping Jia
Journal:  Chin Med J (Engl)       Date:  2015-02-20       Impact factor: 2.628

5.  Acromegaly with empty sella syndrome.

Authors:  Reyna Daya; Faheem Seedat; Khushica Purbhoo; Saajidah Bulbulia; Zaheer Bayat
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-07-01

6.  Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey.

Authors:  Pedro de Pablos-Velasco; Eva María Venegas; Cristina Álvarez Escolá; Carmen Fajardo; Paz de Miguel; Natividad González; Ignacio Bernabéu; Nuria Valdés; Miguel Paja; Juan José Díez; Betina Biagetti
Journal:  Pituitary       Date:  2020-04       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.